Bayer Seeks Speedy EMA Review For Diabetic Kidney Disease Drug Finerenone

 
• By Neena Brizmohun

The developers of three drugs are hoping the European Medicines Agency will decide that their products merit fast-tracking when they are submitted for review for potential pan-EU approval.

Fast speed times clock business working hours moving concept
The EMA has a pathway for fast-tracking its review of new medicines • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards